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Objectives: Cardiomyocyte loss is involved in the transition from compensatory left ventricular hypertrophy (LVH) to heart failure (HF). Our
aim was to investigate the status of the leukaemia inhibitory factor receptor (LIFR)/gp130 survival pathway and its cytoprotective activity in
intact cardiac tissue and in cardiomyocytes obtained from adult spontaneously hypertensive rats (SHR) with LVH (non-failing SHR) and
from aged SHR with overt HF (failing SHR).
Methods: Cardiac morphometry was assayed by planimetry in an image analysis system. mRNA and protein expression were quantified by
real time RT-PCR and Western blotting. Receptors were localized by immunocytochemistry. Trypan blue staining, TUNEL, and MTT cell
viability assays were employed to study the cytoprotective activity of cardiotrophin-1 (CT-1) in isolated caridomyocytes.
Results: Compared to non-failing SHR, failing SHR exhibited enhanced myocardial cell death (pb0.01) demonstrated by the increase in
Bax/Bcl-2 ratio, caspase-3 activation and poly (ADP-ribose) polymerase (PARP) fragmentation. Failing SHR had a 7-fold diminished
expression (pb0.01) of LIFR, no changes in gp130, and 1.6-fold increased myocardial expression (pb0.01) of CT-1. In cardiomyocytes
isolated from non-failing SHR, recombinant CT-1 inhibited apoptotic and non-apoptotic cell death induced by angiotensin II or hydrogen
peroxide. LIFR protein was entirely absent in cardiomyocytes isolated from failing SHR, which were resistant to the cytoprotective effects of
CT-1. Finally, stimulation of non-failing SHR cardiomyocytes with angiotensin II, aldosterone, norepinephrine or endothelin-1 significantly
decreased (pb0.01) LIFR expression.
Conclusions: These data suggest that loss of CT-1-dependent survival mechanisms may contribute to the increase of cell death associated
with HF in SHR. Neurohumoral activation may contribute to this alteration via suppression of LIFR.
© 2007 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.Keywords: Cardiomyocytes; Cardiotrophin-1; Heart failure; Hypertension; LIF receptor; SHR1. Introduction
Accompanying hypertensive heart disease (HHD), the
myocardium initially develops adaptative left ventricular
hypertrophy (LVH) which ultimately leads to cardiac dys-
function and development of congestive heart failure (HF).⁎ Corresponding author. Centre for Applied Medical Research (CIMA).
Avda. Pio XII, 55. 31008. Pamplona. Spain. Tel.: +34 948 19 47 00x3023;
fax: +34 948 19 47 16.
E-mail address: fortuto@unav.es (M.A. Fortuño).
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doi:10.1016/j.cardiores.2007.04.025During this transition, cardiomyocyte loss facilitates both
contractility deterioration and side-to-side slippage of the
remaining cardiomyocytes, leading to ventricular dilation in
HF [1]. Several mechanical and humoral factors present in
pressure-overloaded hearts induce cardiomyocyte death
[2,3]. Alternatively, the loss of contractile cells may reflect
deterioration of intrinsic survival pathways that protect car-
diomyocytes from external death factors.
The heterodimer constituted by the leukaemia inhibitory
factor receptor (LIFR) and the glycoprotein 130 (gp130) is a
signaling transducer that triggers the best characterizeded by Elsevier B.V. All rights reserved.
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gand binding to the low affinity 190 kDa LIFR induces
heterodimerization with gp130 resulting in the high affinity
receptor. JAKs constitutively associated with the cytoplasmic
domains of the two receptors are activated by trans-or
autophosphorylation and in turn phosphorylate tyrosine
residues in both LIFR and gp130, creating approaching
sites for downstream signaling molecules [8,9]. Cardiotro-
phin-1 (CT-1) is the most important ligand of this receptor in
the heart [10,11]. In terminally differentiated cardiomyocytes
this cytokine induces cell survival against ischemic and non-
ischemic death stimuli via ERK1/2 and PI3K/Akt pathways
[12,13] and promotes hypertrophy through ERK5 and STAT3
signaling pathways [14].
Previous studies have shown that mice with cardiac-
specific inactivated gp130 displayed massive induction of
cardiomyocyte apoptosis, chamber dilation and fulminant
HF in response to acute pressure overload, suggesting the
importance of this survival mechanism in situations of
mechanical overload [15]. The spontaneously hypertensive
rat (SHR) is an animal model of genetic hypertension which,
similar to humans, develops HF with aging after a long
period of compensatory hypertrophy [16,17]. The enhanced
cardiomyocyte cell death exhibited by SHR at different ages
is a pathogenic factor that contributes to cardiac deterioration
[18–22]. We have previously shown that cardiomyocytes
isolated from adult SHR are more susceptible to apoptosis
than cardiomyocytes isolated from normal rats, although the
specific origin of this predisposition remains unknown [23].
We hypothesize here that alterations in the LIFR/gp130
survival pathway leading to diminish cytoprotective action of
CT-1 may facilitate cell death and contribute to the transition
from compensated LVH toHF in SHR. To test this hypothesis
we have analyzed the expression of this pathway and its
association with cardiomyocyte death in adult SHR with
LVH (non-failing SHR) and old SHR with overt HF (failing
SHR). In addition, experiments assaying the functionality of
the CT-1 activated LIFR/gp130 pathway were performed on
cardiomyocytes isolated from the two groups of animals.
2. Methods
2.1. Animals
The investigation was performed in accordance with the
Guide for Care and Use of Laboratory Animals published by
the US National Institutes of Health (NIH Publication no. 82–
23, revised in 1996). Animals were provided by Harlam UK
Limited (Bicester, England). All rats were housed in individual
cages and fed a standard rat chow and tap water ad libitum.
Animals were maintained in a quiet room at constant temper-
ature (20 to 22 °C) and humidity (50 to 60%). For ex vivo
determinations, we employed 30-week-old SHR (N=20, non-
failing group), and 76-to 80-week-old SHR with manifest HF
(N=20, failing group). HF diagnosis was performed by
clinical criteria previously reported for this animal model[16,17]. Animals over 72 weeks of age were observed daily by
two independent experts, to achieve a description of normal
activity, responsiveness to manipulation, weight, respiration,
and general aspect. All SHR included in failing group
exhibited 3 of the following symptoms for at least 2 weeks:
weight loss, lethargy, subcutaneous edema, increased respira-
tory rate and effort. Age-matched normotensive Wistar Kyoto
rats (WKY, N=10 per group) were employed to evaluate
aging-induced cardiac cell death in the absence of hyperten-
sion. Systolic blood pressure was measured by the standard
tail-cuff method using a LE 5007 Pressure Computer (Letica
Scientific Instruments). Animals were sacrificed by decapita-
tion under anesthesia i.p. with Ketamine 75 mg/kg (Imalgene
1000, Merial) and Xilacine 5 mg/kg (Rompun, Bayer). After
sacrifice, HF diagnosis was confirmed in the failing group by
the presence of ascites, internal congestion and other signs
such us hepatomegaly or pleural effusion. Hearts were
extracted, weighed to obtain the cardiac index (CI, cardiac
weight in milligrams/body weight in grams) and immediately
frozen in liquid nitrogen for molecular studies, or fixed by
immersion in 10% buffered formalin during 48 hours and
embedded in paraffin for morphometric determinations.
For the study employing isolated cardiomyocytes, SHR were
sacrificed as described above and the hearts were excised for
cardiomyocyte isolation.
2.2. Morphometry
Myocardial dimensions were determined in 5 μm-thick
sections stained with haematoxylin as recently described [14].
Left ventricular wall thickness (LVWT) was measured in three
different regions of left ventricle free wall in quadruplicate.
Chamber diameter (ChD) and chamber area (ChA) were
measured in triplicate. All measurementswere performed in an
automated image analysis system (Soft Imaging System
Analysis) by two blinded observers. Images were calibrated
with known standards.
2.3. Western blotting
Left ventricles or cultured cardiomyocytes were homoge-
nized in lysis buffer containing 7mol/L urea; 2mol/L thiourea;
65 mmol/L CHAPS; 65 mmol/L DTT. Protein concentration
was determined by the Bradford method (Bio-Rad). Proteins
(20 μg) were separated by 12% (for CT-1, Bax and Bcl-2),
10% (forAkt-P, Akt, Bad-P, Bad and Caspase-3) and 7.5% (for
PARP, gp130 and LIFR) SDS polyacrylamide gel electropho-
resis and transferred to PVDF membranes (Amersham
Biosciences). The following primary polyclonal antibodies
were employed: CT-1 (a kind gift from Dr Martínez, Area of
Genetic Therapy, CIMA), Bax, Bcl-2, gp130 and LIFR (Santa
Cruz Biotechnology), Akt, Akt-P (Ser473), Bad, Bad-P
(Ser112), caspase-3, and PARP (Cell Signaling). Blots were
visualized using ECL-Plus chemiluminiscence detection sys-
tem (Amersham Biosciences). Optical density values were
normalized with β-actin.
Table 1
General parameters and myocardial morphometric analysis of non-failing
(NF) and failing (F) SHR
Parameter NF-SHR (n=10) F-SHR (n=10) p
SBP (mmHg) 233±3 206±2 b0.01
Body weight (g) 432±1 393±7 Ns
Heart weight (g) 1.91±0.01 2.16±0.03 b0.05
CI (mg/g) 4.43±0.02 5.14±0.08 b0.05
LVWT (mm) 41.6±0.6 33.2±1.2 b0.01
LVChD (mm) 25.5±0.4 30.5±0.9 b0.01
Ratio (LVWT/LWChD) 1.63±0.03 1.09±0.04 b0.01
LVChA (μm2) 393±18 490±13 b0.01
CI: cardiac index; LVWT: left ventricle wall thickness; LVChD: left
ventricle chamber diameter; LVChA: left ventricle chamber area.
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Total RNA was extracted from hearts or cardiomyocytes
using Trizol (Invitrogen) and subsequently purified using
QIAGEN's RNeasy Total RNA Isolation kit. Reverse
transcription was performed with 250 ng of total RNA. Real-
time PCR was performed with an ABI PRISM 7000 Sequence
Detection System by using specific TaqMan MGB fluorescent
probes (Applied BioSystems). Constitutive 18S ribosomal
RNA was used as endogenous control. For the relative quan-
titative analysis of unknown samples two calibration curves
were prepared for both the target and the endogenous reference,
representing Ct values as a function of the log amount of
starting material. For each myocardial sample or experimental
condition, the mean quantity of target gene and endogenous
control was obtained from the appropriate standard curve in
triplicate. The SD among these triplicateswas alwaysb0.2. The
mean value of the target gene was divided by the mean value of
the endogenous control to obtain a normalized mean quantity
per sample or experimental condition.
2.5. Isolation of cardiomyocytes
Primary cultures of adult cardiomyocytes were obtained
as recently described [13,14]. The average number of
cardiomyocytes obtained was 2.5×106 in non-failing SHR
and 5.0×105 in failing SHR. Cells were plated in laminin-
precoated (0.5 μg/cm2) culture plates at a density of 104 cells/
cm2 in serum-free Medium 199 with Hanks′salts supple-
mented with 26 mmol/L NaHCO3, 10
−4 mmol/L insulin,
5 mmol/L creatinine, 2 mmol/L l-carnitine, 0,2% BSA,
10−5 mmol/L Ara-C, 5 mmol/L taurine, 100 IU/mL penicil-
lin, 0.1 mg/mL streptomycin, 10mmol/L N-(2-hydroxyethyl)
piperazine-N′2-ethanolsulfonic acid (HEPES), pH 7.4. After
4 h of pre-incubation, attached cells were ready for exper-
iments. In cell death assessments, cardiomyocytes were
incubated overnight with angiotensin II (10− 7 mol/L)
(Sigma) or H2O2 (10
−8 mol/L) (Sigma). Recombinant murine
CT-1 (R&D Systems) was added at 10−9 mol/L 1 h prior to
the addition of death stimuli. To investigate the regulation of
LIFR expression, cells isolated from non-failing SHR were
incubated with angiotensin II (10−7 mol/L), aldosterone
(10−6 mol/L) (Fluka), norepinephrine (10−7 mol/L) (Sigma),
endothelin-1 (10−8 mol/L) (Sigma) or CT-1 (10−9 mol/L) for
3 h for mRNA analysis and 24 h for protein determination.
2.6. Cell death assessment in isolated cells
After treatment, trypan blue (Sigma) was directly added
to culture medium at a final dilution of 0.04% (v/v). At least
350 cells per well were counted under a phase contrast
microscope, and total cell death was expressed as the per-
centage of dead (blue) cells per total cells. Measurement of
cell death in this methodology is based on the incapacity of
dead cells to exclude trypan blue, and thus includes both
apoptotic and oncotic cell death. In situ detection of cardio-myocyte apoptosis was performed by means of fluorescent
Annexin V staining and TUNEL labeling as recently de-
scribed [13]. The analysis was performed with an epifluor-
escence-inverted microscope equipped with three filters that
allowed detection of 4′-6-diamino-2 phenylindole (DAPI),
FITC and Alexa 568-stained cells. For quantitation, only
cells exhibiting positive staining for Annexin Vand TUNEL
were recorded as apoptotic. A minimum of 500 nuclei was
counted in each preparation and the apoptotic index was
expressed as the percentage of apoptotic nuclei per total
nuclei. Cell viability was determined in cells plated in 96
well plates using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) cell respiration assay
(Roche), which assesses mitochondrial activity in living
cells, according to the manufacturer's instructions.
2.7. Immunostaining
Cardiomyocytes plated in glass-covered 2 cm2 wells were
fixed in 3% formaldehyde in PBS, during 15 min at 37 °C.
After blockade with 3% bovine serum albumin (BSA) in PBS,
rabbit anti-gp130 or rabbit anti-LIFR antibodies (Santa Cruz
Biotechnology) were incubated during 1 h at 1:500 dilution in
PBS and fluorescein-conjugated goat anti-rabbit secondary
antibody (Sigma) was added for 30 min at 1:1000. After
washing, cells were mounted in DAPI-containing medium
(Vectashield), proteins were viewed with an epifluorescence-
inverted microscope and images captured using a digital
camera. Negative controls excluding primary and secondary
antibodies were included in each experiment.
2.8. Statistical analysis
Results are presented as mean±standard error, computed
from the average measurements obtained from each experi-
mental condition or from each group of animals. Normal
distribution of data was checked by the Shapiro Wilks test and
the homogeneity of variances was tested by a Levene statistical
test. The unpaired Student's t test or the Mann Whitney U test
was used to assess statistical differences between the two
groups of animals or two experimental conditions. p values
lower than 0.05 were considered significant.
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3.1. Blood pressure and left ventricular dimensions
General animal data and parameters describing left ven-
tricle morphometry are shown in Table 1. Compared with
non-failing SHR, failing rats exhibited decreased (pb0.01)
systolic blood pressure, and increased heart weight and left
ventricle ventricular dimensions (both, pb0.05).
3.2. Cell death and LIFR/gp130 pathway in the intact hearts
As shown in Fig. 1, failing SHR exhibited higher myo-
cardial Bax expression (8.3±0.9 vs 4.1±0.5 arbitrary units,Fig. 1. Myocardial apoptosis in non-failing and failing SHR. Three approaches we
(panel A) to obtain the ratio Bax/Bcl-2 as an index of apoptosis susceptibility; m
protease (panel B); and quantification of PARP fragmentation (panel C) by measurin
Western blot and the histogram with bars representing the mean+standard error (N
protein. ⁎, pb0.01 vs NF-SHR. NF-SHR: non-failing SHR; F-SHR: failing SHR.pb0.01) and lower Bcl-2 expression (1.1±0.8 vs 7.6±0.3
arbitrary units, pb0.01) than non-failing SHR. Thus the
index of apoptosis susceptibility, Bax/Bcl2, was higher in
failing SHR than in non-failing SHR (7.0±0.7 vs 0.6±0.2,
pb0.01). Myocardial activation of caspase-3, assayed by
the ratio caspase-3/procaspase 3, was higher in failing
than in non-failing SHR (10.4±0.8 vs 1.3±0.3, pb0.01).
Finally, both the large (85 KDa) and the small (b50 KDa)
fragments of PARP were more abundant in failing SHR than
in non-failing SHR (large, 11.3±0.21 vs 5.3±0.25 arbitrary
units, and small, 2.8±0.25 vs 1.1±0.27 arbitrary units, both
pb0.01) (Fig. 1). To ensure that the higher apoptosis
observed in failing SHR was associated with HF rather than
with aging, the three parameters were determined in age-re employed to assay apoptosis: determination of Bax and Bcl-2 expression
easurement of procaspase-3 and caspase-3 to estimate the activation of this
g large (85 kDa, left) and small fragments (b50 kDa, right). A representative
=10) of the ratio protein to β-actin obtained in triplicate are shown for each
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susceptibility Bax/Bcl-2 was 0.69±0.07 in 30 weeks-old
WKY and 1.56±0.70 arbitrary units in 75 weeks-old WKY.
The ratio caspase 3/procaspase 3 was 0.71±0.22 in
30 weeks-old WKY and 0.93±0.24 arbitrary units in
75 weeks-old WKY. Whereas PARP small fragments wereFig. 2. Myocardial LIFR/gp130 survival pathway expression. LIFR (panel A), gp1
Western blotting. For mRNA analysis in the left part of each panel, the mean+standa
18S are plotted. For proteins, a representativeWestern blot and the histogramwith ba
obtained in triplicate in the two groups of animals are shown (right). The degree of A
rats was assayed by Western blotting and the mean+standard error (N=10) are plotvery scarce in the two groups WKY, large fragments were
1.67±0.69 arbitrary units in 30-week-old WKY and 2.56±
0.86 arbitrary units in 75-week-old WKY. Thus, age-
matched WKY had lower ( pb0.01) apoptotic parameters
than failing SHR, indicating that HF rather than aging is the
main inductor of apoptosis in this model.30 (panel B) and CT-1 (panel C) were quantified by real time RT-PCR and
rd error (N=10) values of the target genes normalized with the internal control
rs representing themean+standard error (N=10) of the ratio protein toβ-actin
kt and Bad phosphorylation (panel D) in the myocardium of the two groups of
ted. ⁎, pb0.01 vs NF-SHR. NF-SHR: non-failing SHR; F-SHR: failing SHR.
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and protein expression of LIFR, gp130 and CT-1, determined
in the two groups of rats. Compared to non-failing SHR,
failing SHR exhibited decreased (pb0.01) LIFR expres-
sion (mRNA: 0.54±0.25 vs 3.8±0.6 arbitrary units; protein:
0.51±0.07 vs 2.52±0.22 arbitrary units) and similar expres-
sion of gp130. Additionally, myocardial expression of CT-1
was higher (pb0.01) in failing SHR than in non-failing
SHR (mRNA: 13.5±1.2 vs 8.9±1.4 arbitrary units; protein:
1.9±0.1 vs 1.2±0.1 arbitrary units). We have previously
reported that binding of CT-1 to LIFR/gp130 induces sur-
vival in adult cardiomyocytes via PI3K-Akt and Bad phos-
phorylation [13]. Thus, we next assayed the degree of
phosphorylation of these signaling molecules in theFig. 3. LIFR and gp130 expression in cardiomyocytes isolated from non-failing and fa
target gene was performed in triplicate and normalized with the internal control 18S. Pr
represent the mean+standard error of three independent cell isolations. ⁎, pb0.01 vs N
proteins (panels C and F). Representative phase-contrast photomicrographs of each cultu
gp130 (panel F). Experiments in triplicate yielded similar results. Magnification 400×myocardium of non-failing and failing rats. As shown in
Fig. 2 (panel D), the phosphorylation of both Akt and Bad
proteins was lower (pb0.01) in the myocardium of failing
SHR than in the myocardium of non-failing SHR.
3.3. Studies in isolated cardiomyocytes
To clarify whether the differences observed in myocardial
LIFR expression specifically affected contractile cells, both
gp130 and LIFR subunits were assayed in cardiomyocytes
isolated from the two groups of rats. Whereas no changes
were found in the expression of gp130 in cells from the two
groups of rats, mRNA and protein expression of LIFR was
lower (pb0.01) in cardiomyocytes from failing SHR than iniling SHR. For mRNA quantification, real-time PCR (panels A and D) of each
oteins were quantified byWestern blotting in triplicate (panels B and E). Values
F-SHR. Fluorescent immunocytochemistry was employed to visualized the two
re are shown beside the corresponding fluorescein staining for LIFR (panel C) or
. NF-SHR: non-failing SHR; F-SHR: failing SHR.
Fig. 4. CT-1 survival effects in isolated cardiomyocytes. Cytoprotective effects of CT-1 (10−9 M) in cardiomyocytes isolated from non-failing and failing SHR were
assayed by trypan blue exclusion (panel A), TUNEL (panel B) andMTT (panel C). Values represent themean+standard error of at least 350 cells in trypan blue assay, at
least 500 nuclei in TUNEL and 8wells from96 plates inMTT. Experiments performed in cell isolations yielded similar results. ⁎,pb0.01 vs baseline; $,pb0.01 vs death
stimulus; pb0.01 vs NF-SHR. NF-SHR: non-failing SHR; F-SHR: failing SHR. ANG II: angiotensin II; CT-1: cardiotrophin-1.
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B). Moreover, LIFR was not detected by immunocytochem-
istry in failing cardiomyocytes (Fig. 3, panel C).
We next explored whether the decrease in LIFR had any
functional effect in cardiomyocytes from failing SHR by
analysing the responsiveness to the ligand CT-1. As illus-
trated in Fig. 4 (Panels A and B), recombinant CT-1 inhibited
(pb0.01) total and apoptotic cell death induced by angio-
tensin II or H2O2 in cardiomyocytes from non-failing SHR.
In addition, CT-1 increased cell viability when cells were
exposed to the same stimuli (Fig. 4, panel C). As previously
reported [13], the protective effects of CT-1 were blocked in
the presence of specific antibodies against LIFR (90% and
94% for angiotensin II and H2O2 respectively) or gp130
(88% and 95% for angiotensin II and H2O2 respectively) and
CT-1 alone exerted no effect on cardiomyocytes (data not
shown). Recombinant CT-1 exerted no cytoprotective effectin cells from failing SHR exposed to either angiotensin II or
H2O2 (Fig. 4, panels D to F). Cardiomyocytes isolated from
failing SHR exhibited higher (both pb0.01) total and
apoptotic cell death in baseline conditions and after
incubation with any of the two death stimuli (Fig. 4).
3.4. Neurohumoral regulation of LIFR expression in
isolated cardiomyocytes
To explore potential repressors of LIFR expression,
cardiomyocytes from non-failing SHR were incubated with
neurohumoral factors known to be elevated in HF. As shown in
Fig. 5, angiotensin II, aldosterone, norepinephrine and
endothelin-1, as well as the ligand CT-1, decreased (pb0.01)
LIFR mRNA and protein levels in this cell type. These results
together with the observation noted above that CT-1 protects
non-failing cardiomyocytes against angiotensin II-induced cell
Fig. 5. Regulation of LIFR expression in isolated cardiomyocytes. Cardiomyo-
cytes isolated from non-failing SHRwere incubated during 3 (for mRNA assay)
or 24 h (for protein assay) with the shown stimuli as described in Methods.
Changes in LIFR mRNA expression (panel A) were assayed by real-time PCR
and normalized with the internal control 18S in triplicate. The histograms with
bars represented the mean+standard error (N=3). Results were referred to
baseline conditions considered 1. Changes in LIFR protein were assayed by
Western blotting (panel B) in triplicate. A representative Western blot and the
histogram with bars represented the mean+standard error of the ratio protein to
β-actin (N=3). ANG II: angiotensin II; CT-1: cardiotrophin-1; ALD:
aldosterone; NE: norepinephrine; ET-1: endothelin-1.
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induced by these two ligands (Fig. 5) is not high enough to
completely blunt CT-1 survival actions in these cells.
4. Discussion
The major findings reported here are the following:
1) compared with non-failing SHR, failing SHR exhibit
diminished myocardial LIFR expression in association with
impaired activation of the intracellular LIFR/gp130-dependent
cytoprotective pathway (Akt and Bad phosphorylation), and
with higher apoptotic cell death, 2) cardiomyocytes isolated
from failing SHR do not express LIFR and are resistant to the
cytoprotective actions of CT-1, and, 3) neurohumoral agonists
that are increased in HF down-regulate LIFR expression in
cardiomyocytes isolated from non-failing SHR.
A critical role of the LIFR/gp130 survival pathway in the
maintenance of left ventricle morphometry and function under
pressure overloading conditions has been previously demon-
strated in mice with cardiac-specific inactivation of gp130.
Whereas hearts from wild-type mice exhibited compensatorymyocardial hypertrophy after transverse aortic constriction, the
conditional mutants with the LIFR/gp130 survival pathway
inactive developed massive cardiomyocyte apoptosis, chamber
dilation and HF [15]. Here, we report that cardiomyocytes from
failing SHR are resistant to the protective actions of CT-1,
probably because of the low expression of LIFR. In addition,
we show that hearts from failing SHR do not preserve the
cytoprotection conferred by the LIFR/gp130 pathway, as
shown by the low activation of the Akt-Bad intermediates
and by the high apoptotic cell death observed. Taken together,
these data suggest that down-regulation of LIFR and
subsequent loss of cardiomyocyte survival mechanisms may
contribute to the increase in myocardial cell death present in
SHR with overt HF.
An emerging question to address is the mechanism that
leads to LIFR down-regulation in the failing hearts. One
possibility points to the mechanisms of protein degradation.
Besides the proteosomal degradation shared with its homolo-
gous gp130 and oncostatin M receptor (OSMR), only LIFR
is susceptible to lysosomal degradation via ERK1/2
mediated phosphorylation in its cytoplasmic domain [24].
We here observed that the major components of neurohu-
moral reflex characteristically activated in HF decrease LIFR
protein expression. Interestingly, all the agonists tested here,
including CT-1, are able to activate the ERK1/2 signaling
pathway in adult cardiomyocytes [13,25,26] and they thus
might induce LIFR degradation by this pathway. A second
possibility points to the mechanism of LIFR turnover regu-
lation in response to CT-1, LIF or oncostatin M (OSM)
binding, which has been reported to be different from its two
homologous. Whereas the initial ligand-induced degradation
of the three receptors is followed by a compensatory increase
in gp130 and OSMR synthesis, LIFR expression remains
low [27,28]. Our data showing that CT-1 reduces LIFR
mRNA and protein in vitro, add the terminally differentiated
cardiomyocyte to the list of cells employing this turnover
regulation, and lead us to speculate that the induction of
LIFR gene transcription, if present, is not efficient enough to
compensate protein degradation. Furthermore, the high CT-1
expression found in the hearts of failing SHR may suggest a
role for the excessive cytokine in LIFR down-regulation.
Finally, changes in histone 3 acetylation in the promoter
region of LIFR might also be involved in the low mRNA
expression observed, since inhibition of deacetylases has
been reported to induce LIFR transcription associated with
the promoter acetylation in various cell lines [29]. Although
the existence of an inverse correlation between the two
phenomena has not been demonstrated, the possibility that
LIFR down-regulation observed in cardiac tissue and
in cardiomyocytes from failing SHR is associated with
histone 3 deacetylation in the promoter region should be
investigated.
The finding that gp130 expression is unchanged in failing
SHR, confirms previous findings in Dahl-sensitive rats with
and without HF [30]. Moreover, several types of in vitro
evidence support the notion that gp130 is more stable than
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similarities shared by the two subunits, specific differences
have been reported regarding their signaling properties [32]
and the molecular mechanisms that regulate their turnover
[27]. Although it is established that gp130 is necessary for
LIFR recruitment and signal triggering [10,11], the loss of
LIFR is enough to inhibit LIFR/gp130 signaling [28]. Thus,
further studies are required to clarify the real significance
that changes in each subunit expression may have in the
pathological myocardium.
The enhanced myocardial expression of CT-1 in the
transition from LVH to HF found in SHR is in accordance
with results obtained in other experimental models of HF
such as Dahl salt-sensitive rats [30] and paced dogs [33].
Previous studies have shown that mechanical stretch,
angiotensin II and norepinephrine induce CT-1 expression
in cardiac cells [34–37]. Our data support the hypothesis that
the two major mechanisms potentially involved in the
increase of myocardial CT-1 in HF are, on the one hand, the
higher mechanical stress present in the failing myocardium,
and on the other hand, the enhanced neurohumoral reflex
present in HF. However, future studies will clarify this
aspect.
In summary, data here presented suggest a role for de-
pressed LIFR/gp130 mediated cytoprotective mechanisms in
the increase of cardiomyocyte death characteristic of the
transition from LVH to HF in SHR. Our findings suggest that
neurohumoral agonists may be involved in such alteration
thus adding information about the mechanisms through
which activation of neurohumoral reflex may be deleterious
in overt HF.
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